Axial Spondyloarthritis (axSpA) Treatment Market Will Grow at Highest Pace Owing to Increasing Prevalence of Ankylosing Spondylitis

Axial Spondyloarthritis (axSpA) Treatment Market Will Grow at Highest Pace Owing to Increasing Prevalence of Ankylosing Spondylitis

Axial spondyloarthritis (axSpA) refers to a chronic inflammatory disease that primarily affects the sacroiliac joints and vertebrae of the spine. The condition causes back pain and stiffness that often improves with exercise but worsens with inactivity. There are two subtypes of axSpA - non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS). Symptoms of axSpA usually develop gradually in late adolescence or early adulthood.

The axial spondyloarthritis (axSpA) treatment market is estimated to be valued at USD 6.02 billion in 2024 and is expected to reach USD 10 billion by 2031, growing at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2031.

Key Takeaways

Key players operating in the Axial Spondyloarthritis (axSpA) Treatment are AbbVie Inc., Novartis AG, Pfizer Inc., UCB Pharma, Eli Lilly and Company. AbbVie dominates the axSpA treatment market with its blockbuster anti-TNF biologics, Humira.

The growing prevalence of axial spondyloarthritis globally is expected to drive the market growth during the forecast period. According to the Spondylitis Association of America, Ankylosing Spondylitis (AS) affects around 0.5% of the population worldwide.

Advancements in biologics for axSpA treatment have expanded treatment options beyond NSAIDs and lifted disease management to a newer level. Biologics directly target particular molecules involved in the disease process, leading to fewer side effects compared to conventional drugs. New biologics in the pipeline can further boost the Axial Spondyloarthritis (axSpA) Treatment Market.

Market Trends
Rising preference for biosimilars: Expanding patent expiries of major biologics and increasing healthcare cost containment are encouraging the development and adoption of affordable biosimilar drugs for axSpA.

Combination therapy gaining traction: Combining biologics with disease-modifying antirheumatic drugs (DMARDs) is being increasingly used to improve treatment efficacy in patients with partial response to anti-TNFs or those who experienced anti-TNF failure.

Market Opportunities
Underdiagnosis of axSpA provides scope for enhancing disease awareness and early identification of cases. Only about 50% of cases are estimated to be diagnosed.

Significant unmet needs persist in managing axial pain, functional impairment, extra-articular features in some patients. This opens up opportunities for novel mechanism therapies targeting different disease pathways.

Impact of COVID-19 on Axial Spondyloarthritis (axSpA) Treatment Market Growth
The COVID-19 pandemic has impacted the growth of the axial spondyloarthritis (axSpA) treatment market. During the peak of pandemic, there was decrease in the number of new axSpA cases diagnosed due to less hospital visits and cancellations/postponement of non-urgent medical procedures. The social distancing norms and lockdowns enforced globally disrupted the supply chain and manufacturing of drugs. This caused a shortage of essential medicines in the market. However, with vaccination drives and resumption of economic activities, the market is recovering gradually. The focus is on teleconsultations and home delivery of drugs to facilitate continuous treatment of patients. The demand for biological disease-modifying anti-rheumatic drugs (bDMARDs) is expected to rise in the post-pandemic period as they are more effective compared to other conventional therapies.

Geographical Regions with High Axial Spondyloarthritis (axSpA) Treatment Market Value
North America dominates the axSpA treatment market currently in terms of value, owing to the high healthcare expenditure and early diagnosis rates in countries like the US and Canada. According to estimates, over 300 million people are affected by spondyloarthritis worldwide and among them, close to 2 million patients suffer from axSpA in North America alone. Europe is the second largest regional market for axSpA treatment driven by growing patient pool and demand for advanced drugs in major countries such as Germany, UK and France.

Fastest Growing Region for Axial Spondyloarthritis (axSpA) Treatment Market
Asia Pacific region is poised to witness the highest growth in the axSpA treatment market during the forecast period. This is attributed to factors like rising awareness about rheumatic diseases, growing disposable income, increasing government initiatives for better healthcare access and emergence of prominent players expanding manufacturing facilities in Asia Pacific countries like China and India. Moreover, the prevalence of axSpA is also relatively high in Asian populations compared to other regions globally. All these factors are contributing towards Asia Pacific emerging as the fastest growing regional market for axSpA treatment.

Get More Insights On- Axial Spondyloarthritis (axSpA) Treatment market

Get This Report in Japanese Language: 軸性脊椎関節炎（axSpA）治療市場

Get This Report in Korean Language: 축성 척추관절염(axSpA) 치료 시장

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.

(https://www.linkedin.com/in/ravina-pandya-1a3984191)